HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Liquid biopsies provide extensive information, but technology carries ‘potential for overuse’
-
- Lower dose IMRT effective for select patients with HPV positive oropharyngeal cancer
- Hazard ratios are potential biohazards Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Commentary: CMS should use caution when implementing lung cancer screening
- Bevacizumab, chemotherapy combination extended PFS in platinum-resistant ovarian cancer
- False-positive mammograms increased short-term anxiety
- Lower initial sorafenib doses did not adversely affect thyroid cancer outcomes
- Thrombolytic therapy for PE reduced mortality, increased major bleeding risk
- Weekly carboplatin, paclitaxel shows promise in advanced ovarian cancer
-
- High adenoma detection rate decreased risk for colorectal cancer, death
- PD-1 antibody demonstrated encouraging activity in metastatic melanoma
- Addition of nivolumab to sunitinib or pazopanib induced response in mRCC
- Combination regimen extended PFS in multiple myeloma
- Ramucirumab plus chemotherapy improved outcomes in advanced NSCLC
- Ruxolitinib decreased hematocrit, spleen volume in hydroxyurea-resistant polycythemia vera
- Investigational treatment increased radiologic PFS, did not improve OS in mCRPC
- Lenalidomide, rituximab achieved responses in treatment-naive patients with follicular lymphoma
-
- Emerging data will determine role of ramucirumab in treatment of advanced gastric cancer Van Nguyen, PharmD, BCOP